scholarly journals Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users

1999 ◽  
Vol 53 (7) ◽  
pp. 434-435 ◽  
Author(s):  
B. P. Smyth ◽  
E. Keenan ◽  
J. J. O'Connor
Keyword(s):  
Hepatitis C ◽  
Harm Reduction ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Short Term ◽  
Harm Reduction Programme ◽  
The Impact

Cost-effectiveness of Harm Reduction in Preventing Hepatitis C among Injection Drug Users

2001 ◽  
Vol 21 (5) ◽  
pp. 357-367 ◽  
Author(s):  
Harold A. Pollack
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Harm Reduction ◽  
Injection Drug Users ◽  
Drug Users ◽  
Injection Drug ◽  
Syringe Exchange ◽  
Short Term ◽  
Incidence Analysis ◽  
The Impact

Objectives. Hepatitis C (HCV) has emerged as a major epidemic among injection drug users (IDUs), with observed prevalence exceeding 70% in many American and European cities. This article explores the potential of syringe exchange programs (SEPs) to reduce HCV incidence and prevalence. Design. A random-mixing epidemiological model is used to examine the potential impact of harm reduction interventions. Methods. Steady-state analysis is used to scrutinize the impact of SEP on HCV incidence and prevalence and to examine the accuracy of short-term incidence analysis in predicting long-run program effects. Results. SEP is predicted to have little impact on HCV incidence and prevalence within realistic populations of IDUs. Conclusions. Short-term incidence analysis substantially overstates SEP effectiveness and cost-effectiveness in preventing HCV. More comprehensive harm reduction models, coupled with referral of active IDUs to treatment, must complement syringe exchange to successfully contain highly infectious blood-borne diseases.

Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?

Addiction ◽  
2013 ◽  
Vol 108 (6) ◽  
pp. 1070-1081 ◽  
Author(s):  
Anneke S. de Vos ◽  
Jannie J. van der Helm ◽  
Amy Matser ◽  
Maria Prins ◽  
Mirjam E. E. Kretzschmar
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Harm Reduction ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Hepatitis C Virus Infection

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

Addiction ◽  
2011 ◽  
Vol 106 (11) ◽  
pp. 1978-1988 ◽  
Author(s):  
Katy M. E. Turner ◽  
Sharon Hutchinson ◽  
Peter Vickerman ◽  
Vivian Hope ◽  
Noel Craine ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Substitution Therapy ◽  
Opiate Substitution Therapy ◽  
The Impact

Hepatitis C prevalence in injecting drug users in Europe, 1990–2007: impact of study recruitment setting

2012 ◽  
Vol 141 (3) ◽  
pp. 563-572 ◽  
Author(s):  
M. RONDY ◽  
L. WIESSING ◽  
S. J. HUTCHINSON ◽  
C. MATHEÏ ◽  
F. MATHIS ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Logistic Model ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Study Recruitment ◽  
Hcv Prevalence ◽  
Random Intercept ◽  
Prevalence Estimates ◽  
Low Threshold ◽  
The Impact

SUMMARYMonitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged. Predictors of HCV positivity were sought through a multilevel analysis using a mixed-effects logistic model, with study identifier as random intercept. HCV prevalence ranged from 21% to 86% across the studies. Overall, HCV prevalence was higher in IDUs recruited in drug treatment centres compared to those recruited in low-threshold settings (74% and 42%, respectively, P < 0·001). Recruitment setting remained significantly associated with HCV prevalence after adjustment for duration of injecting and recent injection (adjusted odds ratio 0·7, 95% confidence interval 0·6–0·8, P = 0·05). Recruitment setting may have an impact on HCV prevalence estimates of IDUs in Europe. Assessing the impact of mixed recruitment strategies, including respondent-driven sampling, on HCV prevalence estimates, would be valuable.

scholarly journals Scottish report on hepatitis C and injecting practices has implications for policy and harm reduction strategies

2004 ◽  
Vol 8 (16) ◽  
Author(s):  
A Taylor ◽  
A Fleming ◽  
Jeanne Rutherford ◽  
D Goldberg
Keyword(s):  
Hepatitis C ◽  
Harm Reduction ◽  
Drug Users ◽  
Hiv Transmission ◽  
Injecting Drug Users ◽  
Syringe Exchange ◽  
Hepatitis C Infection ◽  
Considerable Evidence ◽  
Reduction Strategies

There is considerable evidence that needle/syringe exchange provision has helped to control HIV transmission among injecting drug users (IDUs) [1]. However, the indications are that current interventions may be reducing, but are not controlling, the spread of hepatitis C infection (HCV) [2].

Sign in / Sign up

Export Citation Format

Share Document